Oculis Holding AG
NASDAQ:OCS · NASDAQ Global Market
-$0.28 today
Vol 0.75M · Avg 0.65M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-48.1%
avg -26.0%
ROIC
-39.6%
avg -78.9%
ROA
-40.0%
avg -69.3%
Analysis
ROIC is currently the strongest return metric at -39.6% versus its period average of -78.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Sharon Klier | Chief Development Officer | — | — | — | — | — |
Rebecca Weil | Chief Commercial Officer | — | — | — | — | — |
Sylvia Cheung | Chief Financial Officer | — | — | 51 | — | — |
Virginia R. Dean | Chief Human Resources Officer | — | — | 60 | — | — |
Riad Sherif | Chief Executive Officer & Director | — | — | 58 | — | — |
Snehal Shah | President of Research & Development | — | — | — | — | — |
Ramin Tadayoni | Chief Scientific Officer | — | — | — | — | — |
Páll Ragnar Jóhannesson | Chief Business Officer | — | — | 44 | — | — |
Gudrun Bachmann | Chief Technology Officer | — | — | — | — | — |
Katie Kazem | Chief Legal Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | +180.8% (6yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Forward estimates point to Revenue at +180.8% (6yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
AnaptysBio, Inc.
NASDAQ:ANAB
$2.40B
Kodiak Sciences Inc.
NASDAQ:KOD
$1.87B
UroGen Pharma Ltd.
NASDAQ:URGN
$1.58B
Mind Medicine (MindMed) Inc.
MNMD
$1.56B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.49B
Nektar Therapeutics
NASDAQ:NKTR
$1.17B
Xencor, Inc.
NASDAQ:XNCR
$942.65M
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$870.14M
Sana Biotechnology, Inc.
NASDAQ:SANA
$855.75M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$610.42M
Who manages OCS?
Oculis Holding AG (OCS) lists 10 active executives. The top listed executive is Sharon Klier, Chief Development Officer.
Explore More
Continue the stock analysis
Jump to another research area for this company.